Step 1 topics → Hematology and Oncology → Antimetabolites

Antimetabolites

USMLE Step 1 trap: Confuses MTX's target (DHFR) with thymidylate synthase, which is 5-FU's target. Methotrexate inhibits dihydrofolate reductase (DHFR), preventing regeneration of THF and indirectly depleting the thymidylate synthase substrate needed for dTMP synthesis.

Antimetabolites are a class of chemotherapy agents that structurally mimic normal cellular building blocks — folate, purines, or pyrimidines — and sabotage DNA/RNA synthesis from the inside. USMLE Step 1 loves this class because each drug has a distinct mechanistic target — and the most dangerous wrong assumption is that leucovorin always acts as a rescue agent. It rescues from methotrexate toxicity but potentiates 5-FU toxicity by stabilizing its inhibitory complex with thymidylate synthase. Getting leucovorin's role backwards means getting any paired-drug question wrong. You need to know not just what each drug does, but where exactly in the pathway it hits and what happens downstream.

The exam tests antimetabolites at multiple levels. Pure recall questions ask you to match drugs to targets. Application questions give you a clinical scenario — a patient on MTX developing mucositis, or a leukemia patient on 6-MP started on allopurinol for gout — and ask what happens next and why. Passage-based questions may describe a biochemical pathway and ask you to predict where a drug intervenes or why a rescue strategy works. The trickiest questions exploit the fact that leucovorin plays opposite roles depending on which drug it's paired with: it rescues from MTX toxicity but potentiates 5-FU toxicity. Students who memorize 'leucovorin = rescue' without understanding the mechanism will get burned.

The other classic trap is hydroxyurea — students see it used in CML or sickle cell disease and assume it must be an alkylating agent because those are the 'cancer drugs.' It's not. It's an antimetabolite that inhibits ribonucleotide reductase. Similarly, methotrexate hits DHFR, not thymidylate synthase — that's 5-FU's target. These target mix-ups are exactly what USMLE Step 1 is designed to catch, so locking in the mechanism for each agent is non-negotiable.

From real student decks
89%have cards covering this topic
68%have mature cards
1median lapses in 14 days

Common misconceptions

Common mistake
Wrong: Methotrexate directly inhibits thymidylate synthase.
Right: Methotrexate inhibits dihydrofolate reductase (DHFR), preventing regeneration of THF and indirectly depleting the thymidylate synthase substrate needed for dTMP synthesis.
MTX's actual target is DHFR, the enzyme that converts dihydrofolate back to tetrahydrofolate (THF). Without THF, there's no methylene-THF to donate a methyl group to dUMP, so thymidylate synthase is starved of its substrate and dTMP synthesis collapses — but the enzyme itself is not blocked by MTX. Thymidylate synthase is 5-FU's direct target. Keeping these two drugs on separate branches of the same pathway is the key to avoiding this confusion on USMLE Step 1.
Common mistake
Wrong: Leucovorin rescues cells from MTX toxicity by blocking MTX binding to DHFR.
Right: Leucovorin (folinic acid) is a reduced folate that bypasses DHFR entirely, directly supplying THF to normal cells without competing with MTX.
Leucovorin (folinic acid) is a pre-reduced form of folate that enters the one-carbon pool downstream of DHFR, completely bypassing the step MTX blocks. It does not displace MTX from DHFR or compete with it. Normal rapidly-dividing cells (gut epithelium, bone marrow) can receive the THF they need through leucovorin while tumor cells — which typically have lower folate uptake capacity at rescue doses — remain depleted. The rescue works by circumvention, not competition.
Common mistake
Wrong: Leucovorin rescues patients from 5-FU toxicity just as it does from MTX toxicity.
Right: Leucovorin enhances 5-FU toxicity by stabilizing the 5-FU–thymidylate synthase–folate ternary complex, making it an adjuvant rather than a rescue agent for 5-FU.
Leucovorin's role flips entirely when it's combined with 5-FU. 5-FU gets converted to FdUMP, which forms a covalent ternary complex with thymidylate synthase and the folate cofactor methylene-THF. Leucovorin increases the pool of methylene-THF, stabilizing this complex and locking the enzyme in its inhibited state longer. The result is enhanced cytotoxicity, not rescue — which is exactly why leucovorin is used as an adjuvant in colorectal cancer regimens like FOLFOX. Memorize the rule: leucovorin rescues MTX, but potentiates 5-FU.
Common mistake
Wrong: Allopurinol is safe to co-administer with 6-mercaptopurine because both are used in leukemia management.
Right: Allopurinol inhibits xanthine oxidase, which normally degrades 6-MP; co-administration causes 6-MP accumulation and severe toxicity, requiring a 75% dose reduction.
Xanthine oxidase is the main enzyme responsible for catabolizing 6-MP into inactive metabolites. Allopurinol irreversibly inhibits xanthine oxidase to reduce uric acid in gout or tumor lysis syndrome — but this simultaneously blocks 6-MP degradation. The drug accumulates to toxic levels, causing profound myelosuppression. If the combination cannot be avoided, 6-MP dose must be reduced by 75%. The clinical scenario of a leukemia patient on 6-MP who develops gout or tumor lysis is a classic Step 1 setup for this interaction.
Common mistake
Wrong: Hydroxyurea is an alkylating agent because it is used in CML and sickle cell disease.
Right: Hydroxyurea is an antimetabolite that inhibits ribonucleotide reductase, blocking deoxyribonucleotide synthesis and arresting cells in S phase.
Hydroxyurea is an antimetabolite, not an alkylating agent. Its target is ribonucleotide reductase, the enzyme that converts ribonucleotides to deoxyribonucleotides (rNDPs → dNDPs). Blocking this step cuts off the supply of DNA building blocks and arrests cells in S phase. Its clinical uses — CML, polycythemia vera, essential thrombocythemia, and sickle cell disease (where it induces HbF) — reflect its ability to suppress rapidly proliferating cells, but the mechanism has nothing to do with DNA alkylation.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Identify dihydrofolate reductase (DHFR) as methotrexate's target enzyme, explain how DHFR inhibition depletes THF and ultimately blocks dTMP synthesis, and predict MTX's classic toxicities (myelosuppression, mucositis, nephrotoxicity) along with when and why leucovorin rescue is used.
  2. Explain that 5-FU inhibits thymidylate synthase and recognize that leucovorin enhances — not rescues from — 5-FU's effect by stabilizing the covalent ternary complex between 5-FU, thymidylate synthase, and the folate cofactor.
  3. Trace 6-mercaptopurine's activation by HGPRT and degradation by xanthine oxidase, and identify why co-administering allopurinol (a xanthine oxidase inhibitor) causes 6-MP accumulation and requires a 75% dose reduction to avoid severe toxicity.
  4. Match the remaining antimetabolites to their mechanisms: cytarabine and gemcitabine as nucleoside analogs that inhibit DNA polymerase and chain-elongate after incorporation, and hydroxyurea as a ribonucleotide reductase inhibitor used in CML, polycythemia vera, and sickle cell disease.

Can you avoid these mistakes?

A patient with rheumatoid arthritis on high-dose methotrexate develops severe mucositis and pancytopenia. What is the mechanism of MTX's toxicity, and how does leucovorin rescue work at the biochemical level — specifically, does it compete with MTX or bypass DHFR entirely?
An oncologist adds leucovorin to a patient's 5-FU regimen for metastatic colorectal cancer. A medical student assumes this is a rescue strategy in case of toxicity. What is the student getting wrong, and what is leucovorin actually doing to 5-FU's effect on thymidylate synthase?
A 10-year-old with ALL is maintained on 6-mercaptopurine. He develops hyperuricemia and is started on allopurinol. Three weeks later he presents with fever, neutropenia, and oral ulcers. What drug interaction explains this presentation, and what adjustment should have been made?
Match each drug to its correct primary mechanism: methotrexate, 5-FU, hydroxyurea, cytarabine. Which one is commonly misclassified as an alkylating agent, and what does it actually inhibit?

Related topics

Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →